EBI2/GPR183

The Epstein-Barr virus (EBV) induced receptor 2 (EBI2; also known as GPR183) is an orphan member of the 7TM receptor family A. EBI2 is a constitutively active seven-transmembrane receptor. EBI2 has been placed in varying 7TM receptor subgroups by different phylogenetic analyses as being a target of peptide or lipid ligands. EBI2 constitutively activates extracellular signal-regulated kinase (ERK) in a pertussis toxin-insensitive manner. EBI2 is up-regulated up to 200-fold in B cells following EBV infection.

EBI2 activation stimulates immune cell migration and has been genetically linked to autoimmune diseases including type 1 diabetes. Small molecule modulators of EBI2 can be useful for probing the function of the receptor and its relevance to human diseases.

Products for EBI2/GPR183

Cat.No. Product Name Information
GC14433 7α,25-dihydroxy Cholesterol A GPR183 agonist
GC31651 GSK682753A
GSK682753A is a selective and highly potent inverse agonist of the epstein-barr virus-induced receptor 2 (EBI2) with an IC50 of 53.6 nM.
GC38820 ML401 ML401, a potent chemical probe, selectively antagonizes EBI2 (also known as GPR183) with an IC50 of 1.03 nM.
GC15430 NIBR189 EBI2 (GPR183) receptor antagonist
GC65986 SAE-14 SAE-14 (compound SAE-14) is a potent, specific GPR183 antagonist with an IC50 value of 28.5 nM, can antagonize 7α, 25-OHC-induced calcium mobilization with IC50 value below 50 nM in HL-60 cells. GPR183 antagonist-1 can reverse allodynia in mice.